Trevor C Huang

US Patent:

20060136050, Jun 22, 2006

Filed:

Mar 3, 2006

Appl. No.:

11/276518

Inventors:

Jack Chu - Santa Rosa CA, US
Scott Doig - Santa Rosa CA, US
Brian Fernandes - Roseville MN, US
Trevor Huang - Maple Grove MN, US
Josiah Wilcox - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/06

US Classification:

623001420

Abstract:

Methods and devices for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed is coating of autologous growth factor compositions onto stent grafts prior to stent graft implantation. Additional embodiments include stent grafts having autologous growth factor composition coatings useful for treating aneurysms.

US Patent:

20070202093, Aug 30, 2007

Filed:

Mar 13, 2007

Appl. No.:

11/685257

Inventors:

Dennis Brooks - Windsor CA, US
Jack Chu - Santa Rosa CA, US
Scott Doig - Santa Rosa CA, US
Trevor Huang - Maple Grove MN, US
Tessy Kanayinkal - Brooklyn Park MN, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/06
A61K 38/48
C12P 21/06

US Classification:

424094640, 623001410, 435384000, 435069100, 424093720

Abstract:

Methods for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed are application of cell growth promoting compositions such as, but not limited to, autologous platelet gel compositions directly to treatment sites during or after stent graft implantation.

US Patent:

20080044852, Feb 21, 2008

Filed:

Apr 26, 2007

Appl. No.:

11/796045

Inventors:

Tessy Kanayinkal - Brooklyn Park MN, US
Laura Yonce - Edina MN, US
Trevor Huang - Maple Grove MN, US
Rohit Cariappa - Bangalore, IN
Kenneth Merte - Southlake TX, US
James Keogh - Maplewood MN, US
Kevin McIntosh - Brooklyn Park MN, US
Brian Steffens - Maple Grove MN, US
Asha Nayak - Santa Rosa CA, US
Erick Johnson - Minneapolis MN, US

International Classification:

C12P 21/06

US Classification:

435068100

Abstract:

The present invention provides biological compositions and methods for making the same.

US Patent:

20080089867, Apr 17, 2008

Filed:

Oct 13, 2006

Appl. No.:

11/580603

Inventors:

Brian Fernandes - Roseville MN, US
Carl A. Schu - Plymouth MN, US
Trevor C. Huang - Maple Grove MN, US
Maura G. Donovan - St. Paul MN, US

International Classification:

A61K 35/14
C12N 5/08

US Classification:

424 937, 435366, 435372

Abstract:

A method of increasing retention, survival and proliferation of transplanted cells in diseased or damaged tissue types or organ by providing transplanted cells with autologously-derived platelet cells and forming a autologously-derived platelet gel prior or during administration to the tissue type or organ through a delivery device and immobilizing the transplanted cells in the tissue type or organ system.

US Patent:

20090105630, Apr 23, 2009

Filed:

Nov 30, 2007

Appl. No.:

11/948290

Inventors:

Trevor C. Huang - Maple Grove MN, US
Alford L. McLevish - Maple Grove MN, US
Joseph L. Kalscheuer - Minneapolis MN, US
Roderick E. Briscoe - Rogers MN, US

International Classification:

A61M 1/34

US Classification:

604 609

Abstract:

An arterial line blood filter for use in extracorporeal blood circuits during heart bypass surgery has, among other components, a housing with a cap portion, a base portion, and a generally cylindrical wall portion. The blood filter has a filter element disposed within the housing. An inlet is positioned at an upward angle with respect to the housing and includes an opening in the generally cylindrical wall portion in fluid communication with the inlet chamber. In some embodiments the position of the inlet limits the pressure drop and prime volume of the filter. According to one embodiment, the cap portion has an upwardly sloping inner surface and there is a vent in the cap portion. The inner surface of the cap portion can have a projection proximate the vent configured to limit immobilization of gaseous microemboli within the inlet chamber.

US Patent:

20130144538, Jun 6, 2013

Filed:

Dec 6, 2012

Appl. No.:

13/706453

Inventors:

Lawrence Erickson - Brooklyn Park MN, US
Trevor Huang - Maple Grove MN, US
Tessy Kanayinkal - Brooklyn Park MN, US
Craig Petersen - Brooklyn Park MN, US
Charlene Yuan - Woodbury MN, US

Assignee:

MEDTRONIC, INC. - Minneapolis MN

International Classification:

G01N 33/49

US Classification:

702 19

Abstract:

Activated clotting time (ACT) tests detect blood clotting time based on the viscosity changes of a test sample, using a ferromagnetic washer lifted to the top of a test chamber and then dropped from the top via gravity; a drop time greater than a preset threshold value indicates clotting of the test sample. Blood samples which have high levels of heparin usually produce very weak clots that may easily be destroyed by the lifting movement of the washer. But if the clot threshold is set low to detect the weak clots, false detections occur during early testing cycles when activators are not fully suspended during the mixing cycle. Improved algorithms for lifting the washer and adjusting over time enable accurate detection of weak clots.

US Patent:

20130189789, Jul 25, 2013

Filed:

Jan 24, 2013

Appl. No.:

13/748922

Inventors:

Trevor C. Huang - Maple Grove MN, US
Tessy Kanayinkal - Brooklyn Park MN, US
Mary Jo Passenheim - Coon Parids MN, US

Assignee:

MEDTRONIC, INC. - Minneapolis MN

International Classification:

G01N 33/86

US Classification:

436 69, 422554, 137 1501

Abstract:

High range activated clotting time (HR-ACT) tests detect blood clotting time in blood samples which have high levels of heparin. Reagents such as calcium chloride and kaolin within the test apparatus trigger clotting. Physical separation of the reagents from each other prevents interaction between them before the test sample introduction. In one embodiment, to improve dry kaolin re-suspension, kaolin may be suspended in water rather than buffered saline before being dispensed into the test chamber. The combination of removing the buffered saline and the calcium chloride from the kaolin suspension enables clot detection in blood samples containing 5-6 u/ml of heparin.

US Patent:

20210318308, Oct 14, 2021

Filed:

Mar 16, 2021

Appl. No.:

17/203030

Inventors:

- Santa Rosa CA, US
Trevor Huang - Maple Grove MN, US
Tessy Kanayinkal - Maple Grove MN, US

International Classification:

G01N 33/569
G01N 33/86

Abstract:

A method carried out by a system configured to analyze platelet aggregation includes retaining a ferromagnetic object at an elevation of a chamber in which a sample of blood or plasma is disposed. The ferromagnetic object is retained at the elevation for a period of time. The ferromagnetic object is then released from the elevation. The ferromagnetic object minimal position is measured following the release of the ferromagnetic object. The object minimal position may be correlated with amount of platelet aggregation in the sample.